Aurobindo Pharma Ltd

Stage 2 · Advancing · week 30Setup 6.0 ★ FairStrong +7.2

As of 9 Oct 2026, Aurobindo Pharma is in Stage 2 — advancing, the uptrend phase, in week 30 (since 13 Mar 2026). It closed at ₹1,693, 2.4% below its 52-week high and above its 200-day average, which is rising. In Health Care, 44.6% of stocks are in Stage 2.

Aurobindo Pharma Limited, a biopharmaceutical company, develops, manufactures, commercializes, and sells generic pharmaceuticals, active pharmaceutical ingredients (APIs), and injectables. More about the company

₹1,693
+2.92% today
₹97,411 Cr · Large cap
Market Neutral — FadingHealth Care 44.6% in Stage 2-2.6 pts / 20dPharmaceuticals 51.3%-0.4 pts

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

6.0 ★ Fair

Momentum

Steady

Edge

Strong +7.2

Setup-score rank among Stage 2 peers: #24 of 61 in Pharmaceuticals · #27 of 78 in Health Care

Is AUROPHARMA early, or has it already run? Pro answers that for every NSE stock, after every close.

₹2,999 · 12 months₹1,999 · 6 months
Loading price chart…
vs 52W High
-2.4%
₹1,070.8 lo₹1,734 hi
2.4% below 52W high — pullback range
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 30
1w13w26w
Week 30 — mature, watch for distribution
How long this stock has been in Stage 2. The sweet spot is mid-run — enough time to prove the structure holds, not so long it's extended. Very fresh (wk 1–4) often needs more time to confirm.
vs 200 DMA
18.6%
200 DMA: ₹1,427.3 · rising
Long-term trend anchor. When stock and Nifty are both above their 200 DMA, the macro backdrop supports continuation.
Rel Volume
0.78x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
↗
MA20 gently rising · +0.5% vs MA50 +3.2%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
1M
+0.1%
3M
+8.2%
6M
+26.8%
YTD
+38.3%
1Y
+56.2%
Sector
Health Care
↓ Peaking
Stage 2%
44.6%
20d Δ
-2.6pp
1M return
-4.9%
3M return
+0.2%
Sector Stage-2 % · last 20 days
This stock ranks #17 of 74 Stage 2 stocks in Health Care by RS.
Industry
Pharmaceuticals
→ Flat
Stage 2%
51.3%
20d Δ
-0.4pp
1M return
-4.2%
3M return
-0.6%
Industry Stage-2 % · last 20 days
Ranks #14 of 58 Stage 2 stocks in this industry.
Stage Cycle Timeline2023-07-13 → 2026-10-09
S2 36w
S2 27w
S4 18w
S4 18w
S2 30w
2023-07-132026-10-09
S1S2S3S4Setup score (0–10, dashed line at 5)
S2 36w → S3 6w → S2 27w → S3 8w → S4 18w → S1 8w → S4 18w → S1 3w → S2 11w → S3 4w → S2 30w current
Total tracked: 169 weeks across 11 stage runs.
Scan Membership
Breakout Watch
Latest: 2026-03-13
3 appearances in last 60 days. First seen: 2024-04-29.
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-10-09S2
Wk 30 · Vol 0.78x
2026-10-08S2
Wk 30 · Vol 0.49x
2026-10-07S2
Wk 29 · Vol 0.48x
2026-10-06S2
Wk 29 · Vol 1.13x
2026-10-05S2
Wk 29 · Vol 1.08x
2026-10-01S2
Wk 29 · Vol 1.18x
2026-09-30S2
Wk 29 · Vol 1.27x
2026-09-29S2
Wk 28 · Vol 1.28x
2026-09-28S2
Wk 28 · Vol 0.73x
2026-09-25S2
Wk 28 · Vol 0.69x
2026-09-24S2
Wk 28 · Vol 0.92x
2026-09-23S2
Wk 28 · Vol 1.07x
Sector Peers — Stage 2All →
BAFNAPH
wk 18 · 0.0% from hi
8.6
ZIMLAB
wk 22 · 0.0% from hi
8.3
KILITCH
wk 2 · -7.3% from hi
8.3
SMSPHARMA
wk 3 · -8.0% from hi
8.3
RPGLIFE
wk 16 · -12.0% from hi
7.6
Moving averages & range
50 DMA
₹1,656.7
200 DMA
₹1,427.3
52W High
₹1,734
52W Low
₹1,070.8
5D Low
₹1,645
Resistance levels (recent highs)
20d High
₹1,734
60d High
₹1,734
120d High
₹1,734
250d High
₹1,734
Next resistance
+2.4%
to 20d High
Ask the Market AI about AUROPHARMAAsk →
P/E (TTM)
23.8
Forward 16.2
Earnings Growth (YoY)
+1.9%
Revenue +5.6%
ROE
+9.9%
Profit margin +10.4%
Dividend Yield
0.27%
P/B 2.2
About this companyHealth Care· Pharmaceuticals

Aurobindo Pharma Limited, a biopharmaceutical company, develops, manufactures, commercializes, and sells generic pharmaceuticals, active pharmaceutical ingredients (APIs), and injectables. The company offers formulation in form of oral solids, liquids, injectables, vaccines, and metered dose inhalers; and APIs, biosimilars, and peptides targeting therapeutic areas, such as central nervous system, cardiovascular, respiratory, antibiotics, anti-retroviral, anti-diabetics, gastroenterology, oncology, and dermatology. It also provides antiretroviral drugs for the people and children living with HIV; and API space for sterile and non-sterile penicillin's, cephalosporins, penems, and non-beta lactams. The company has operations in India, the United States, Europe, Puerto Rico, and internationally. The company was incorporated in 1986 and is headquartered in Hyderabad, India.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-09. Past data patterns are not indicative of future results. This page is a data analytics tool only.